Tag: exchange

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

GREENWICH, Conn., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (NYSE: AC) (“AC” or the “Company”) announced today that it has given formal notice to the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist its Class A common stock (the “common stock”) from the NYSE and to deregister under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). Following the de-listing from the NYSE, we expect to provide liquidity to AC’s Class A stock shareholders by listing AC Class A on the OTCQX platform (the “OTCQX”). AC plans on filing a Form 25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about August 25, 2025. The last day of trading in AC’s common stock on the NYSE will be on or about September 4, 2025, when the Form 25 takes effect. Ninety days thereafter, AC’s common stock deregistration is expected to become effective. When AC files Form 15 on or about September 4, 2025, its filing obligations under the Exchange Act will immediately be suspended or terminated, including the filing of all reports on Forms 8-K, 10-Q and 10-K.

CALGARY, Alberta, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") confirms that the monthly dividend with respect to August 2025 of $0.11 per common share is to be paid on September 15, 2025, for shareholders of record on August 31, 2025.

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Water Ways Technologies Inc. (TSXV: WWT) (“Water Ways” or the “Company”), is pleased to announce that further to its news release dated June 18, 2025, the Company has received final acceptance from the TSX Venture Exchange (the “TSXV”) of the consolidation of its outstanding common shares (the “Common Shares”) on the basis of one (1) post-consolidation Common Share for every ten (10) pre-consolidation Common Shares (the “Share Consolidation”).

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the August 2025 monthly cash distribution of €0.005 per Unit and Class B LP Unit (the “August 2025 Distribution”), being equivalent to €0.06 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on August 29, 2025, with payment on September 15, 2025.

Not for distribution to United States newswire services or for dissemination in the United States

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”).

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

Ness Ziona, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced today that it plans to conduct a reverse share split of the Company’s outstanding ordinary shares, no par value per share, at a ratio of 1-for-7 which is expected to be implemented at market open on the Tel-Aviv Stock Exchange on August 24, 2025 and on the Nasdaq Capital Market on August 25, 2025.

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial